-
2024-517793-25-00
1
2026-03-30
Tuberculosis
-
2025-523224-45-00
10
2026-03-30
Untreated, Unresectable or Metastatic Colorectal Cancer
-
2024-518210-81-00
5
2026-03-18
Advanced Hepatocellular Carcinoma
-
2025-524172-29-00
3
2026-03-18
Healthy volunteers
-
2025-524856-73-00
3
2026-03-13
Not Applicable
-
2025-524693-42-00
1
2026-03-09
Stable Coronary Artery Disease (CAD)
-
2025-524674-42-00
4
2026-03-05
Parkinson’s Disease
-
2025-523108-59-00
1
2026-03-04
Severe infections caused by Gram-negative bacteria
-
2024-512040-28-01
6
2026-03-01
Confirmed diagnosis of Alcoholic liver cirrhosis
-
2023-509156-34-02
6
2026-02-17
Chronic Kidney Disease
Kidney Failure
-
2025-524527-46-00
1
2026-02-16
Ocular inflammatory conditions
-
2024-519372-22-00
3
2026-02-12
transthyretin amyloid amyloidosis cardiomyopathy (ATTR-CM)
-
2025-524310-28-00
3
2026-02-02
Epilepsy, amotrophic lateral sclerosis, neuropathy
-
2025-522333-61-00
4
2026-01-23
Hidradenitis suppurativa
-
2025-521917-24-00
5
2026-01-21
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carci
-
2025-523885-25-00
1
2026-01-21
Healthy Volunteers
-
2025-522500-24-00
5
2026-01-20
Head and Neck squamous cell carcinoma
-
2024-519554-37-00
5
2026-01-16
Phenylketonuria
-
2023-507106-13-00
1
2026-01-12
Locally advanced rectal cancer
-
2025-520518-79-00
4
2026-01-06
Atrial Fibrillation
-
2025-521771-31-00
3
2026-01-05
Cervical Cancer
-
2025-522860-34-00
5
2025-12-16
Chronic lymphocytic leukemia (CLL)
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous
-
2025-521398-15-00
5
2025-12-04
Immune system diseases